Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Vella Bonanno, Patricia, Ermisch, Michael, Godman, Brian, Martin, Antony P., Van Den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Eriksson, Irene, Fürst, Jurij, Gad, Mohamed, Greičiūtė-Kuprijanov, Ieva, van der Graaff, Martin, Gulbinovic, Jolanta, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Langner, Irene, Mardare, Ileana, Markovic-Pekovic, Vanda, Magnusson, Einar, Melien, Oyvind, Meshkov, Dmitry O., Petrova, Guenka I., Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Schuurman, Ad, Ramos, Ricardo, Rodrigues, Jorge, Zara, Corinne, Zebedin-Brandl, Eva, Haycox, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://www.ncbi.nlm.nih.gov/pubmed/28878667
http://dx.doi.org/10.3389/fphar.2017.00497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://www.ncbi.nlm.nih.gov/pubmed/28878667
http://dx.doi.org/10.3389/fphar.2017.00497

Ejemplares similares